Clinical trials: Pulmonary Artery Hypertension
Pulmonary Arterial Hypertension
Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH
This is a multicenter, single-arm trial to evaluate the safety of the transition from Selexipag to Remodulin® then Oral Treprostinil in Symptomatic Subjects with Pulmonary Arterial Hypertension (PAH).
- Trial name
- NCT03016468
- Testing
- Parenteral Remodulin (treprostinil) injection, Oral Treprostinil
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain
Prospective, multi-center, open-label, single-arm, Phase 3b psychometric validation study. Primary objectives: To evaluate the psychometric characteristics of reliability and construct validity of the French, Italian and Spanish…
- Trial name
- ORCHESTRA (NCT02081690)
- Testing
- Macitentan
- Where
- 39 sites in France, Italy and 1 more
- Volunteers
- 160 people
- Sponsor
- Actelion
Heart Failure, Congestive, Coronary Arteriosclerosis
After Discharge Management of Low Income Frail Elderly
The purpose of this study is to determine whether comprehensive post-hospitalization interdisciplinary care management can be an effective care delivery model to improve outcomes in low-income frail elderly.
- Conditions
- Heart Failure, Congestive, Coronary Arteriosclerosis, Atrial Fibrillation, Cerebrovascular Accident
- Trial name
- NCT00328848
- Testing
- Behavioral
- Volunteers
- 530 people
- Sponsor
- Summa Health System
Pulmonary Arterial Hypertension
Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)
This clinical trial will study the safety, tolerability, and pharmacodynamics of single doses of MK-8892 in participants with pulmonary arterial hypertension (PAH).
- Trial name
- NCT01934647
- Testing
- MK-8892
- Volunteers
- 7 people
- Sponsor
- Merck Sharp & Dohme LLC
PAH
Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
This was a multi-center, open-label, safety, tolerability and pharmacokinetic study of oral treprostinil in pediatric subjects with stable PAH aged 7 to 17 years who were (1) transitioning from parenteral Remodulin therapy; (2)…
- Trial name
- NCT02276872
- Testing
- oral treprostinil
- Where
- 9 sites in United States
- Volunteers
- 32 people
- Sponsor
- United Therapeutics
Hypertension, Pulmonary
Study Evaluating the Addition of Sildenafil to Bosentan Therapy in Pulmonary Arterial Hypertension
This study will examine the effects of add-on sildenafil to bosentan monotherapy in patients with Pulmonary Arterial Hypertension.
- Trial name
- NCT00780728
- Testing
- Sildenafil
- Sponsor
- University Health Network, Toronto
Pulmonary Arterial Hypertension
Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension
Pulmonary hypertension (PHT) patients often receive long term oral anticoagulants. If the indication is strong, in the secondary chronic thrombo-embolism pulmonary hypertension (CTE-PHT) prevention, the frequent prescription (50…
- Trial name
- HEMA-HTP (NCT02800941)
- Testing
- Oral anticoagulant treatment
- Where
- 4 sites in France
- Volunteers
- 203 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Pulmonary Arterial Hypertension
A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers
This single center, open label, randomized, two-period, two-sequence cross-over study is designed to evaluate the relative bioavailability of a treprostinil diethanolamine 1 mg tablet in reference to treprostinil diethanolamine 1…
- Trial name
- NCT01172496
- Testing
- treprostinil diethanolamine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- United Therapeutics
Coronary Artery Disease, Valvular Heart Disease
Prehabilitation for Patients Undergoing Elective Cardiac Surgery
The objective of this clinical trial is to develop a novel rehabilitation model that, through the PRECICA program, will help to reduce perioperative and postoperative complications in the care process prior to planned cardiac…
- Conditions
- Coronary Artery Disease, Valvular Heart Disease, Chronic Thromboembolic Pulmonary Hypertension, Aortic Diseases
- Trial name
- PRECICA (NCT07704086)
- Testing
- Physical exercise, Educational program and respiration physiotherapy
- Where
- 2 sites in Spain
- Volunteers
- 86 people
- Sponsor
- Hospital Universitario 12 de Octubre
Pulmonary Hypertension, Magnetic Resonance Imaging
4D-flow Cardiac MRI to Assess Pulmonary Arterial Pressure in Pulmonary Hypertension
Due to radiation exposure and low but real risk of morbidity and mortality associated with right heart catheterization, non-invasive procedures to estimate mPAP are desired for the diagnosis of PH or to monitor treatment…
- Conditions
- Pulmonary Hypertension, Magnetic Resonance Imaging, Pulmonary Arterial Pressure, Right Heart Catheterization
- Trial name
- HTPFLUW (NCT05103189)
- Testing
- 4D-flow sequence
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Interstitial Lung Disease
The Six Minute Walk Test: Influence of Instruction on Results
Two - four 6MWT performed according to ATS standards. Each walk however had specifically altered wording and coaching performed in random order to determine differences in outcomes. One walk was done in the standard ATS fashion.
- Trial name
- NCT01789996
- Testing
- alternative six minute walk test, Standard six minute walk test
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Inova Health Care Services
Pulmonary Arterial Hypertension
A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants
This study is designed to describe pulmonary arterial hypertension (PAH) participants in terms of their clinical characteristics, therapies used, disease progression, and outcomes (example, death, hospitalization, risk category…
- Trial name
- CARE PAH (NCT04955990)
- Testing
- PAH Therapies
- Where
- 54 sites in United States, Argentina and 15 more
- Volunteers
- 232 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension, Exercise Training
Home-based Exercise Training in Patients With Pulmonary Arterial Hypertension: Effect on Skeletal Muscular Function and Metabolism
Pulmonary Arterial Hypertension has gone from a disease that causes rapid death to a more chronic condition. Yet, improved survival is associated with major challenges for clinicians as most patients remain with poor quality of…
- Conditions
- Pulmonary Arterial Hypertension, Exercise Training, Home-based Rehabilitation, Exercise Capacity
- Trial name
- NCT04241497
- Testing
- Home-based rehabilitation
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Laval University
Neonatal Diseases and Abnormalities, Neonatal Mortality
Melatonin for Pulmonary Hypertension in Full Term Neonates
Published evidence has provided a possible role of melatonin and the treatment of pulmonary hypertension through its strong antioxidant properties and improving vascular function in animals.
- Conditions
- Neonatal Diseases and Abnormalities, Neonatal Mortality, Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension, Children
- Trial name
- NCT06685679
- Testing
- Melatonin
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Ain Shams University
Pulmonary Arterial Hypertension
Safety and Efficacy of Continued CS1 Treatment of Patients With Pulmonary Arterial Hypertension
CS1-004 will be an extension of the CS1-003 Study. The primary objective of the CS1-004 study is to evaluate long-term safety and tolerability of continued treatment with CS1.
- Trial name
- NCT06321705
- Testing
- CS1
- Where
- Sweden
- Sponsor
- Cereno Scientific AB
Pulmonary Arterial Hypertension
Effects of Iloprost Treatment in Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease
The prevalence of PAH associated with congenital systemic-to-pulmonary shunts in Western countries has been estimated to range between 1.6 and 12.5 cases per million adults, with 25-50% of this population affected by…
- Trial name
- EIGER (NCT01383083)
- Volunteers
- 42 people
- Sponsor
- Maryknoll Medical Center
Pulmonary Arterial Hypertension
A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed Thelin
The Thelin Patient Safety Registry is a post-marketing program in the European Union (EU) that is designed to supplement the reporting of spontaneous adverse events (AE) and better characterize known and potential safety signals…
- Trial name
- PROSE (NCT00995566)
- Testing
- Sitaxentan sodium
- Where
- 4 sites in Belgium, France and 1 more
- Volunteers
- 54 people
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension
Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585
Safety, tolerability, pharmacokinetics (PK), cardiac conduction and food effect study on single and multiple ascending doses of KAR5585 in healthy adults.
- Trial name
- NCT02746237
- Testing
- KAR5585 Capsules
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Karos Pharmaceuticals
Pulmonary Vascular Disorder, Pulmonary Artery Hypertension
HA Residents With PVD, Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) With and Without Supplemental Oxygen Therapy (SOT)
To study the effect of SOT in patients with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH) who permanently live >2500m on pulmonary artery…
- Conditions
- Pulmonary Vascular Disorder, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT06084559
- Testing
- Supplemental oxygen therapy
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- University of Zurich
Congenital Heart Disease, Cardiomyopathy
Evaluation of the Prevalence and Clinical Manifestation of SARS-CoV-2 Infection in a Population of Adult and Pediatric Patients With Congenital Heart Disease
The goal of this observational study, drug-free, cross-sectional, single-center is to describe the incidence and characteristics of the clinical course and any short- and medium-term complications of patients with congenital…
- Conditions
- Congenital Heart Disease, Cardiomyopathy, Pulmonary Arterial Hypertension, SARS CoV-2 Infection
- Trial name
- NCT06784687
- Where
- Italy
- Volunteers
- 2,376 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna